DERUXTECAN NO FURTHER A MYSTERY

Moderate or weak CYP3A4 Inhibitors: Monitor serum potassium for the duration of drug initiation or dosage adjustment of both Kerendia or perhaps the moderate or weak CYP3A4 inhibitor, and alter Kerendia dosage as ideal (seven.one)If this SPL incorporates inactivated NDCs listed through the FDA initiated compliance action, they will be specified as